等待开盘 11-17 09:30:00 美东时间
0.000
0.00%
SCYNEXIS reported completing Phase 1 studies for SCY-770 and IV SCY-247, with plans to initiate Phase 2 trials for both in late 2026 and 2027, respectively. The company secured a $214 million BARDA contract for SCY-247 development and strengthened its leadership team with new CFO and R&D head appointments. Cash reserves of $63.2 million are expected to support operations into 2029.
11-05 13:20
SCYNEXIS, Inc. announced the appointment of Sanjay Subramanian as Chief Financial Officer, effective September 9, 2026, succeeding Ivor Macleod, who is retiring. Subramanian brings over 20 years of experience in finance and business development across the biotech and pharmaceutical sectors. Macleod, who joined SCYNEXIS in 2022, will remain through October 9 to ensure a smooth transition. Subramanian was granted an option to purchase 100,000 share...
09-10 12:00
An announcement from Inozyme Pharma ( ($INZY) ) is now available. Inozyme Pharm...
2025-07-01 21:48
Inozyme Pharma has postponed its 2025 Annual Meeting due to the pending acquisition by BioMarin Pharmaceutical Inc. If the acquisition is completed, the meeting will not be held. If not, the Board may reschedule it with a new record date. Inozyme, a biopharmaceutical company, focuses on bone health and blood vessel function, developing INZ-701 for ENPP1 Deficiency and other conditions.
2025-06-20 21:00
Inozyme Pharma, Inc. ( ($INZY) ) has released its Q1 earnings. Here is a breakd...
2025-06-10 11:51
Inozyme Pharma ( ($INZY) ) has issued an update. On May 16, 2025, Inozyme Pharm...
2025-06-02 19:58